These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36449057)

  • 1. Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review.
    Zekić T; Benić MS
    Rheumatol Int; 2023 Mar; 43(3):559-565. PubMed ID: 36449057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
    Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma.
    Lolli C; Medri M; Ricci M; Schepisi G; Filograna A; De Giorgi U; Stanganelli I
    Medicine (Baltimore); 2018 Dec; 97(52):e13810. PubMed ID: 30593172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
    Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
    Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
    Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
    Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer.
    Badovinac S; Korsic M; Zarkovic K; Mursic D; Roglic M; Jakopovic M; Samarzija M
    Immunotherapy; 2018 Mar; 10(6):427-431. PubMed ID: 29562858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creatinine kinase elevation and peripheral neuropathy during nivolumab treatment of a patient with metastatic renal cell carcinoma.
    Simsek M; Bilici M; Tekin SB
    Indian J Cancer; 2018; 55(4):413-414. PubMed ID: 30829281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor.
    Mathew Thomas V; Bindal P; Ann Alexander S; McDonald K
    J Oncol Pharm Pract; 2020 Mar; 26(2):459-461. PubMed ID: 30909794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review.
    Zeng MF; Chen LL; Ye HY; Gong W; Zhou LN; Li YM; Zhao XL
    Medicine (Baltimore); 2017 Nov; 96(44):e8426. PubMed ID: 29095280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy.
    Johnson ED; Kerrigan K; Butler K; Patel SB
    J Oncol Pharm Pract; 2020 Jan; 26(1):224-227. PubMed ID: 30880569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immune-related adverse events by immune checkpoint inhibitors].
    Kadono T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):83-89. PubMed ID: 28603205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?
    Özyurt E; Özçelik S; Sürmeli H; Çelik M; Ayhan M; Özçelik M
    J Oncol Pharm Pract; 2022 Mar; 28(2):462-465. PubMed ID: 34558355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-induced lichen planus.
    Yilmaz M; Mese SG; Celik U
    J Oncol Pharm Pract; 2020 Apr; 26(3):758-760. PubMed ID: 31382865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.